retatrutide peptide triple hormone receptor agonist From Obesity to Metabolic Health: Why Is a Game-Changer retatrutide peptide injection Retatrutide: breakthrough…

Clinical Effectiveness: SURMOUNT-1 Trial (Tirzepatide 15 mg): Duration: 72 weeks Participants: 2,539 adults with obesity Average Weight Loss: 22.5% of body weight 10 mg Dose: 21.4% weight loss 5 mg Dose: 15.0% weight loss Placebo: 2.4% weight loss 5% Weight Loss: 96% of participants 10% Weight Loss: 89% of participants 15% Weight Loss: 78% of participants 20% Weight Loss: 63% of participants This is the best weight loss result ever achieved with medication in clinical trials

If no insulin comes out after the third time, the needle may be blocked

Your clinician reviews your medical history carefully to minimize risk and ensures dosing is increased safely over time

Honest Care may facilitate clinical trial recruitment for patients who choose to opt in

Some observational data suggest that weight loss achieved through any meansincluding GLP-1 medications, bariatric surgery, or lifestyle modificationmay have modest effects on thyroid function tests in individuals with obesity